tiprankstipranks
Trending News
More News >

Biophytis Pursues Strategic Partnership in China for BIO101

Story Highlights
Biophytis Pursues Strategic Partnership in China for BIO101

Don’t Miss TipRanks’ Half-Year Sale

An update from Biophytis SA ( (FR:ALBPS) ) is now available.

Biophytis SA has entered into exclusive negotiations with a major Chinese pharmaceutical lab to license BIO101 for co-development and commercialization in China, targeting viral respiratory infections, sarcopenia, and obesity. This move aligns with Biophytis’ strategic goals and could significantly enhance its market presence in China, the world’s second-largest pharmaceutical market, potentially benefiting millions of patients.

More about Biophytis SA

Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its main drug candidate being BIO101. The company operates in the biotechnology industry, specializing in muscle, respiratory, and metabolic diseases. It is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil.

YTD Price Performance: -25.71%

Average Trading Volume: 3,160

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €2.78M

Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1